Faculty

Back to Index
Vito Michele Campese, MD
Professor of Medicine
Medicine
IRD 804 2020 Zonal Ave. Off Campus Los Angeles
+1 323 226 7337

Overview

A native of Bari, Italy, Dr. Campese graduated medical school summa cum laude before coming to the Keck School of Medicine on a fellowship in 1974. Since his time at USC, Dr. Campese has established himself as one on the most prominent nephrologists in the field and currently heads Keck’s division of Nephrology.

In addition to his numerous academic and administrative appointments, Dr. Campese is a former president of the Italian-American Society of Nephrologists and is currently a member of the Program Committee on the Council on High Blood Pressure Research for the American Heart Association.

Awards

The Italians Society of Nephrology : Honorary Membership, 2007

University Kidney Disease Research Disease

Rotary Club International: Rotary Club Contribution to Science Award, 2002

The Regione Puglia Targa d'Oro Award for Contribution to Science

The Domenico Cotugno Medal and Award in Nephrology

Publications

Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. J Am Soc Nephrol. 2017 Sep; 28(9):2794-2801. View in: PubMed

Predictors of blood pressure response to spironolactone. J Hypertens. 2016 May; 34(5):845-7. View in: PubMed

The Mesoamerican nephropathy: a regional epidemic of chronic kidney disease? Nephrol Dial Transplant. The Mesoamerican nephropathy: a regional epidemic of chronic kidney disease? Nephrol Dial Transplant. 2016 Mar; 31(3):335-6. View in: PubMed

Statins and the kidney: friend or foe? Lancet Diabetes Endocrinol. Statins and the kidney: friend or foe? Lancet Diabetes Endocrinol. 2015 Mar; 3(3):161-2. View in: PubMed

The Challenges of Blood Pressure Control in Dialysis Patients. Recent Adv Cardiovasc Drug Discov. 2015; 10(1):34-59. View in: PubMed

The Challenges of Blood Pressure Control in Dialysis Patients. Recent Pat Cardiovasc Drug Discov. 2015; 10(1):34-59. View in: PubMed

Left ventricular function and chronic kidney disease: how soon does it start? Nephrol Dial Transplant. Left ventricular function and chronic kidney disease: how soon does it start? Nephrol Dial Transplant. 2014 Nov; 29(11):1989-91. View in: PubMed

Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct; 45(10):2974-82. View in: PubMed

Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol. 2014 Apr; 18(2):291-5. View in: PubMed

Reply to 'resistant hypertension and central aortic pressure'. J Hypertens. 2014 Mar; 32(3):699. View in: PubMed

Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014; 34(5):571-6. View in: PubMed

International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 03; 62(22):2031-45. View in: PubMed

International expert consensus statement: percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013 Dec 3; 62(22):2031-45. View in: PubMed

Interventional hypertension: a new hope or a new hype? The need to redefine resistant hypertension. J Hypertens. 2013 Nov; 31(11):2118-21; discussion 2122. View in: PubMed

Is lipid management effective for all stages of CKD?. Is lipid management effective for all stages of CKD? . Blood Purif. 2013; 35(1-3):26-30. View in: PubMed

Statin use in patients with diabetes and kidney disease: the Japanese experience. J Atheroscler Thromb. 2013; 20(5):407-24. View in: PubMed

Abnormal sympathetic reactivity to the cold pressor test in overweight humans. Am J Hypertens. 2012 Dec; 25(12):1236-41. View in: PubMed

Resistant hypertension and obstructive sleep apnea in end-stage renal disease. J Hypertens. 2012 May; 30(5):880-1. View in: PubMed

IgA nephropathy in a patient with ulcerative colitis, Graves' disease and positive myeloperoxidase ANCA. Clin Nephrol. 2012 Feb; 77(2):146-50. View in: PubMed

Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. Do HMG-CoA reductase inhibitors improve kidney function? The saga continues. J Nephrol. 2011 Sep-Oct; 24(5):550-3. View in: PubMed

Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011 Jan 20; 2011:814354. View in: PubMed

"Zero ischemia" partial nephrectomy: novel laparoscopic and robotic technique. Eur Urol. 2011 Jan; 59(1):128-34. View in: PubMed

Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011; 2011:814354. View in: PubMed

Reevaluating the use of antihypertensive medications, a first step toward reducing polypharmacy in very old patients. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):621-4. View in: PubMed

Aldosterone in the pathogenesis of chronic kidney disease and proteinuria. Curr Hypertens Rep. 2010 Aug; 12(4):303-6. View in: PubMed

Adverse drug responses: An increasing threat to the well-being of older patients: Comment on "Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients 65 years or older". Arch Intern Med. 2010 Jul 12; 170(13):1148-9. View in: PubMed

Oxidative stress and sympathetic activity in hypertension. Am J Hypertens. 2010 May; 23(5):456. View in: PubMed

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis. 2010 Apr; 55(4):671-81. View in: PubMed

Angiotensin receptor blocker telmisartan improves insulin sensitivity in peritoneal dialysis patients. Perit Dial Int. 2010 Jan-Feb; 30(1):66-71. View in: PubMed

Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children. Pediatr Nephrol. 2009 Dec; 24(12):2301-7. View in: PubMed

Aldosterone and hypertension in African Americans. Am J Hypertens. 2009 Dec; 22(12):1234. View in: PubMed

The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med. 2009 Jun 08; 169(11):1015-8. View in: PubMed

The hazards of dual renin-angiotensin blockade in chronic kidney disease. Arch Intern Med. 2009 Jun 8; 169(11):1015-8. View in: PubMed

Lixivaptan: a novel vasopressin receptor antagonist. Expert Opin Investig Drugs. 2009 May; 18(5):657-62. View in: PubMed

Regional expression of NAD(P)H oxidase and superoxide dismutase in the brain of rats with neurogenic hypertension. Am J Nephrol. 2009; 29(5):483-92. View in: PubMed

Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol. 2008 Dec; 105(6):1873-6. View in: PubMed

Exercise pressor reflex in humans with end-stage renal disease. Am J Physiol Regul Integr Comp Physiol. 2008 Oct; 295(4):R1188-94. View in: PubMed

Increased cardiovascular events in hypertensive patients with insulin resistance: a 13-year follow-up. Nutr Metab Cardiovasc Dis. 2008 May; 18(4):314-9. View in: PubMed

HMG-CoA reductase inhibitors and renal function. Clin J Am Soc Nephrol. 2007 Nov; 2(6):1100-3. View in: PubMed

Diuretics are preferred over angiotensin II-converting enzyme inhibitors for initial therapy of uncomplicated hypertension. Am J Kidney Dis. 2007 Aug; 50(2):197-202. View in: PubMed

A vitamin-E-fortified diet reduces oxidative stress, sympathetic nerve activity, and hypertension in the phenol-renal injury model in rats. J Am Soc Hypertens. 2007 Jul-Aug; 1(4):242-50. View in: PubMed

HMG-CoA reductase inhibitors and the kidney. Kidney Int. 2007 Jun; 71(12):1215-22. View in: PubMed

Regional expression of NO synthase, NAD(P)H oxidase and superoxide dismutase in the rat brain. Brain Res. 2007 Feb 23; 1134(1):27-32. View in: PubMed

Clinical characteristics of resistant hypertension: the importance of compliance and the role of diagnostic evaluation in delineating pathogenesis. J Clin Hypertens (Greenwich). 2007 Jan; 9(1 Suppl 1):7-12. View in: PubMed

The kidney and hypertension: over 70 years of research. J Nephrol. 2006 Nov-Dec; 19(6):691-8. View in: PubMed

Use of antagonists of aldosterone in patients with chronic kidney disease: Potential advantages and risks. J Hypertens. 2006 Nov; 24(11):2157-9. View in: PubMed

Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension. 2006 Aug; 48(2):309-15. View in: PubMed

Metabolic risk factors and markers of cardiovascular and renal damage in overweight subjects. Am J Hypertens. 2006 Apr; 19(4):426-31. View in: PubMed

Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. Hypertension in renal parenchymal disease: why is it so resistant to treatment? Kidney Int. 2006 Mar; 69(6):967-73. View in: PubMed

HMG-CoA reductase inhibitors and the kidney. Curr Hypertens Rep. 2005 Oct; 7(5):337-42. View in: PubMed

ACE inhibitors: over two decades of use. J Clin Hypertens (Greenwich). 2005 Sep; 7(9):531-7. View in: PubMed

Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2005 Sep; 46(3):533-9. View in: PubMed

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005 Jul; 46(1):45-51. View in: PubMed

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005 Mar; 16 Suppl 1:S11-7. View in: PubMed

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005 Jan; 45(1):2-14. View in: PubMed

Antihypertensive drugs and the kidney. Curr Cardiol Rep. 2004 Nov; 6(6):403-8. View in: PubMed

Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol. 2004 Aug; 287(2):H695-703. View in: PubMed

ImmunoDip: an improved screening method for microalbuminuria. Am J Nephrol. 2004 May-Jun; 24(3):284-8. View in: PubMed

Evolving role of calcium antagonists in the management of hypertension. Med Clin North Am. 2004 Jan; 88(1):149-65. View in: PubMed

A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications. Clin Exp Nephrol. 2003 Sep; 7(3):167-71. View in: PubMed

Chronic renal injury-induced hypertension alters renal NHE3 distribution and abundance. Am J Physiol Renal Physiol. 2003 May; 284(5):F1056-65. View in: PubMed

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis. 2003 Mar; 41(3):565-70. View in: PubMed

Responses of proximal tubule sodium transporters to acute injury-induced hypertension. Am J Physiol Renal Physiol. 2003 Feb; 284(2):F313-22. View in: PubMed

Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens. 2002 Aug; 15(8):717-24. View in: PubMed

High salt intake inhibits nitric oxide synthase expression and aggravates hypertension in rats with chronic renal failure. J Nephrol. 2002 Jul-Aug; 15(4):407-13. View in: PubMed

Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002 Jun; 15(6):557-64. View in: PubMed

Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension. 2002 Jun; 39(6):1101-6. View in: PubMed

Neurogenic factors in renal hypertension. Curr Hypertens Rep. 2002 Jun; 4(3):256-60. View in: PubMed

Downregulation of neuronal nitric oxide synthase and interleukin-1beta mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension. 2002 Feb; 39(2 Pt 2):519-24. View in: PubMed

Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol (1985). 2008 Dec; 105(6):1873-6. View in: PubMed

Powered bySC CTSI